Method for producing immortalised antibodies-secreting cells
A method for producing immortalized antibody-secreting cells, comprising: (a) providing a transgenic animal having antibody-secreting cells capable of expressing one or more transgenes, wherein the antibody-secreting cells are in a non-immortalized state in the absence of a stimulus and are capable of changing to an immortalized state by means of the transgene or transgenes upon exposure of the cells to the stimulus; (b) extracting the antibody-secreting cells from the animal; and (c) exposing the antibody-secreting cells to the stimulus, thereby immortalizing the antibody secreting cells by means of the transgene or transgenes.
1. A method for producing immortalised antibody-secreting cells, comprising:
(a) providing a germline transgenic mouse having antibody-secreting cells capable of expressing one or more transgenes, wherein the antibody-secreting cells are in a non-immortalised state in the absence of a stimulus and change to an immortalised state by means of the transgene or transgenes upon exposure of the cells to the stimulus;
(b) extracting the antibody-secreting cells from the mouse; and
(c) exposing the antibody-secreting cells to the stimulus, thereby immortalising the antibody-secreting cells by means of the transgene or transgenes.
2. A method for producing antibodies, comprising producing immortalised antibody-secreting cells by a method as defined in claim 1 , and collecting antibodies from the cells.
3. A method for preparing a clonal population of immortalised cells which produce a monoclonal antibody, comprising:
(a) providing a germline transgenic mouse having antibody-secreting cells capable of expressing one or more transgenes, wherein the antibody-secreting cells are in a non-immortalised state in the absence of a stimulus and change to an immortalised state by means of the transgene or transgenes upon exposure of the cells to the stimulus;
(b) extracting the antibody-secreting cells from the mouse;
(c) exposing the antibody-secreting cells to the stimulus, thereby immortalising the antibody-secreting cells by means of the transgene or transgenes;
(d) selecting an immortalised antibody-secreting cell which produces the antibody, and
(e) preparing the clonal population of immortalised cells from the immortalised antibody-secreting cell.
4. A method according to claim 1 , wherein expression of a transgene in the antibody-secreting cells is under the control of an inducible promoter, and the stimulus is capable of regulating activity of the promoter and transgene expression.
5. A method according to claim 4 , wherein the stimulus promotes promoter activity and transgene expression.
6. A method according to claim 4 , wherein the stimulus inhibits promoter activity and transgene expression.
7. A method according to claim 1 , wherein a product of a transgene in the antibody-secreting cells promotes immortalisation in the presence of the stimulus, and does not promote immortalisation in the absence of the stimulus.
8. A method according to claim 1 , wherein the transgene is an oncogene.
9. A method according to claim 8 , wherein the oncogene is a gene for the large T antigen.
10. A method according to claim 1 , wherein the transgenic mouse is an immortomouse.
11. A method according to claim 1 , wherein a product of a transgene in the antibody-secreting cells inhibits immortalisation in the absence of the stimulus, and does not inhibit immortalisation in the presence of the stimulus.
12. A method according to claim 11 , wherein the transgene is a tumour suppressor gene.
13. A method according to claim 1 , wherein a product of a transgene in the antibody-secreting cells inhibits a tumour suppressor function in the cells.
14. A method according to claim 13 , wherein the transgene is mdm2.
15. A method according to claim 13 , wherein the transgene comprises cre recombinase, the tumour suppressor function results from a tumour suppressor gene, and the tumour suppressor gene, or a functional part thereof, is flanked with loxp sites.
16. A method according to claim 13 , wherein a product of the transgene comprises an antisense RNA or ribozyme RNA which is capable of inhibiting expression of a tumour suppressor gene.
17. A method according to claim 12 , wherein the tumour suppressor gene comprises p53.
18. A method according to claim 8 , wherein the oncogene comprises myc, abl, bcl-2, v-rel, ras, papillomavirus E6 protein, papillomavirus E7 protein, adenovirus EIA, PIM1, RhoH/TTF or PAX5.
19. A method according to claim 1 , wherein the transgenic mouse comprises antibody-secreting cells in which a tumour suppressor gene has been deleted.
20. A method according to claim 1 , wherein the method comprises the further step of immunising the transgenic mouse with an antigen before step (b).
21. A method according to claim 20 , further comprising selecting an antibody-secreting cell which produces an antibody which recognises the antigen.
22. A method according to claim 3 , wherein step (d) comprises fluorescence activated cell sorting.
23. A method according to claim 1 , wherein the transgenic mouse is not immunised.
24. A method according to claim 1 , wherein the stimulus comprises a temperature change.
25. A method according to claim 1 , wherein the stimulus comprises a chemical stimulus.
26. A method according to claim 1 , wherein the antibody-secreting cells are B lymphocytes.
27. A method according to claim 1 , wherein the antibody is a humanised antibody.
28. A method according to claim 1 , comprising a further step of storing the antibody-secreting cells at a temperature of 0° C. or below, after extracting the antibody-secreting cells from the mouse, and before or after exposing the antibody-secreting cells to the stimulus.
29. A method for producing a monoclonal antibody, comprising producing a population of immortalised cells by a method as defined in claim 3 , and producing the monoclonal antibody from the population of immortalised cells.
30. A method according to claim 13 , wherein the tumor suppressor function comprises p53.
31. A method for producing antibodies comprising:
(a) providing a germline transgenic mouse having antibody-secreting cells capable of expressing one or more transgenes, wherein the antibody-secreting cells are in a non-immortalised state in the absence of a stimulus and change to an immortalised state by means of the transgene or transgenes upon exposure of the cells to the stimulus;
(b) extracting the antibody-secreting cells from the mouse;
(c) exposing the antibody-secreting cells to the stimulus, thereby immortalising the antibody-secreting cells by means of the transgene or transgenes; and
(d) collecting antibodies from the antibody-secreting cells, wherein the antibody-secreting cells are B lymphocytes.
32. A method for producing antibodies comprising:
(a) providing a germline transgenic mouse having antibody-secreting cells capable of expressing one or more transgenes, wherein the antibody-secreting cells are in a non-immortalised state in the absence of a stimulus and change to an immortalised state by means of the transgene or transgenes upon exposure of the cells to the stimulus, which mouse has been immunised with an antigen;
(b) extracting the antibody-secreting cells from the mouse;
(c) exposing the antibody-secreting cells to the stimulus, thereby immortalising the antibody-secreting cells by means of the transgene or transgenes; and
(d) collecting antibodies from the antibody-secreting cells.